Current oral antiplatelet agents to prevent atherothrombosis

Cerebrovascular Diseases

Volumn 11, Issue SUPPL. 2, 2001, Pages 11-17

  Hankey, Graeme J ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Antiplatelet agents; Stroke

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PROSTAGLANDIN SYNTHASE; THROMBOXANE; TICLOPIDINE;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY STENT; DIARRHEA; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; RASH; THROMBOCYTE ACTIVATION; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

ADMINISTRATION, ORAL; ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; THROMBOSIS;

EID: 0035062393     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049139     Document Type: Conference Paper

References (44)

1. Coronary artery disease in combat casualties in Vietnam
2. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥62 years of age
3. Antiplatelet therapy
4. Platelet GP IIb/IIIa antagonists: The first anti-integrin receptor therapeutics
5. Platelet GP IIb-IIIa blockers
6. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
7. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin
8. Aspirin as an antiplatelet drug
9. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results
10. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
11. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke
12. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials
13. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials
14. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
15. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
16. European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
17. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
18. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
19. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials
20. The effect of ticlopidine on TIA compared with aspirin: A double-blind twelve-month and open 24-month follow-up study
21. Open randomised study comparing ticlopidine with acetylsalicylic acid in the prevention of contralateral thrombosis in patients initially presenting with unilateral thrombosis
22. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
23. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
24. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet in unplanned and elective coronary stenting: The Full Anticoagulation versus Aspirin plus Ticlopidine (FANTASTIC) study
25. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)
26. A clinical trial comparing three antithrombotic-drug regimes after coronary-artery stenting
27. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
28. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
29. Ticlopidine or Plavix Post-Stent (TOPPS): Randomization to 2-week treatment
30. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
31. Clopidogrel versus ticlopidine after intracoronary stent placement
32. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
33. A comparison of clopidogrel to ticlopidine therapy for the prevention of major adverse cardiac events at thirty days and six months following coronary stent implantation
34. Short term mortality lower with clopidogrel than ticlopidine following coronary artery stenting
35. Dipyridamole plus aspirin in cerebrovascular disease
36. Different antiplatelet regimens in the prevention of vascular events among patients at high risk of stroke: New evidence from the Antithrombotic Trialists' Collaboration
37. Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin
38. Toward a new frontier in myocardial perfusion therapy: Emerging platelet pre-eminence
39. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
40. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: Evaluation of oral xemilofiban in controlling thrombotic events
41. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multi-center randomized trials
42. Future perspectives for optimizing oral antiplatelet therapy
43. Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial